TheraCell
TheraCell is a privately held Northridge, California-based biotechnology company founded in 2008 that develops two patented platform technologies enabling stereotactic transplantation of neurons and therapeutic cells into the brain.
- Company typePrivate
- Founded2008
- HeadquartersNorthridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What TheraCell does
TheraCell is a privately held biotechnology company, founded in 2008 and headquartered in Northridge, California, that develops two patented platform technologies for stereotactic transplantation of neurons and therapeutic cells into the brain. The company sits at the intersection of neuroscience, cell therapy, and neurosurgical device engineering, focused on enabling precise, minimally invasive delivery of neural cells into the central nervous system — an application aimed at neurological indications where conventional small-molecule and biologic therapeutics have demonstrated limited efficacy. The platform-centric technology posture is consistent with a business model anchored to intellectual property development, potential research collaborations, and downstream therapeutic or licensing optionality rather than direct product commercialization.
The organization is structured as a small, research-intensive operation of 1-10 employees led by Bradley Patt (Chairman & Chief Executive Officer), Andrew J. Carter (CTO), and Nelson Scarborough (Chief Scientific Officer), indicating a technically driven leadership profile. To date, TheraCell has funded operations through two modest equity rounds recorded in the source data — a $1,344,000 raise on 2009-09-03 and a $75,000 raise on 2015-03-17 — totaling approximately $1.42M in disclosed capital across more than fifteen years. The combination of a multi-year gap in financing activity, micro-cap raises, an absence of disclosed revenue, and no documented commercial partnerships, license deals, or product milestones establishes an early-stage, pre-revenue operating profile oriented toward sustaining preclinical research and intellectual property protection.
TheraCell firmographics
Firmographics- Name
- TheraCell
- Website
- https://theracellinc.com
- Company type
- Private
- Founded year
- 2008
- Headcount range
- 1–10 employees
- Short description
- TheraCell is a privately held Northridge, California-based biotechnology company founded in 2008 that develops two patented platform technologies enabling stereotactic transplantation of neurons and therapeutic cells into the brain.
- Ownership category
- akta.pro rank
TheraCell industry classification
Industry- Product category
- Neurosurgical Cell Delivery Platforms
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industry
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
Keywords
Where TheraCell is headquartered
LocationHeadquarters
- HQ city
- Northridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TheraCell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Autologous Therapy Products: Sale of Magellan and Precise autologous concentration systems and associated kits for creating PRP, cBMA, and PPP therapies
- Allograft Products: Sale of allograft-derived products including Influx product line (ProteiOS, Fibrant, SPARC, PLUS, Sponge) derived from donor tissue
- Synthetic Bone Grafts: Sale of InQu biosynthetic bone graft products for spinal fusion and orthopedic procedures
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
TheraCell product offering
Product offeringCore offering
TheraCell develops two patented platform technologies that facilitate stereotactic transplantation of neurons and therapeutic cells into the brain. The company focuses on neurosurgical instrumentation and delivery platforms designed to enable precise cell-based therapies for central nervous system indications.
Differentiator
Problem solved
Functional benefit
Products and services
- Patented Stereotactic Neuron Transplantation Platform
- Patented Therapeutic Cell Delivery Platform
Quantifiable outcome
- InQu biosynthetic bone graft outperforms fusion rates of ICBG (iliac crest bone graft)
Companies that use TheraCell
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles1 record
TheraCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
TheraCell partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- PhysicianscorePhysicians and surgeons worldwide partner with Isto Biologics to use orthobiologic products and provide clinical feedback for product development and improvement
- DistributorscoreMedical product distributors partner with Isto Biologics to market and distribute orthobiologic products including Magellan, Influx, and InQu to healthcare facilities
- Hospital AdministratorsminorHospital administrators evaluate and procure Isto Biologics products for institutional use in orthopedic and spinal procedures
- ResearchersminorMedical researchers partner with Isto Biologics for clinical research support and studies involving orthobiologic products
Scale indicators2 records
Recent moves2 records
Expansion highlights1 record
TheraCell competitors and assessment
Company assessmentDirect peers
- Renishaw (Neuromate / neurosurgery): Maker of the Neuromate stereotactic neurosurgical robot used for DBS, stereo-EEG, and cell therapy implantation. Directly comparable as an established device-side peer addressing the same stereotactic delivery workflow TheraCell's platform targets.
- Aspen Neuroscience: Developer of autologous iPSC-derived dopamine neuron cell therapies for Parkinson's disease that require stereotactic surgical delivery into the striatum. Comparable because it represents the most direct addressable market for TheraCell's stereotactic neuron transplantation platform.
- BrainStorm Cell Therapeutics: Clinical-stage developer of autologous cell therapies (NurOwn) for neurodegenerative diseases including ALS and MS. Highly comparable to TheraCell because both operate in the CNS cell therapy delivery space and require stereotactic or surgical cell implantation infrastructure to administer their therapies.
- Lineage Cell Therapeutics: Clinical-stage allogeneic cell therapy developer with programs in spinal cord injury (OPC1) and neurodegenerative retinal disease, both requiring precise surgical cell delivery. Comparable to TheraCell as a peer targeting the same intersection of cell therapy and CNS surgical delivery.
- BlueRock Therapeutics: Bayer-owned pluripotent stem cell therapy developer focused on Parkinson's disease and other CNS indications using surgical cell implantation into the brain. Directly comparable as both a CNS cell therapy developer and a likely customer for stereotactic delivery platforms like TheraCell's.
Broad incumbents
- Brainlab: Established surgical navigation and stereotactic neurosurgery platform whose systems are routinely used for precision intracranial delivery. Comparable as a potential competitor or partner for TheraCell's stereotactic delivery platform, with broader neurosurgery footprint and established hospital channels.
- Sana Biotechnology: Well-capitalized cell and gene therapy platform developing hypoimmune allogeneic cell therapies across oncology, type 1 diabetes, and CNS indications. Comparable to TheraCell as a potential strategic acquirer or partner of stereotactic delivery technology for its CNS programs.
Emerging players
- Q Therapeutics: Clinical-stage developer of neural cell therapies (Q-Cells) for CNS conditions including transverse myelitis, ALS, and spinal cord injury. Comparable to TheraCell because it is a smaller, focused neural cell therapy developer whose commercial path depends on precise CNS delivery.
- Atara Biotherapeutics: Allogeneic T-cell and cell therapy developer with CNS and oncology indications that rely on precise cell delivery methods. Comparable as a modality-platform peer whose pipeline economics depend on the kind of stereotactic and surgical delivery infrastructure TheraCell provides.
- Notch Therapeutics: Developer of iPSC-derived engineered immune and stem cell therapies with an emerging CNS focus. Comparable as a smaller, modality-platform peer whose cell products would require the kind of stereotactic delivery technology TheraCell develops.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks3 records
Key highlights4 records
Customer concentration
TheraCell social profiles
Digital presenceTheraCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
TheraCell leadership team
Management profileNumber of profiles
Profiles1 record
TheraCell funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TheraCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TheraCell
What does TheraCell do?
TheraCell develops two patented platform technologies that facilitate stereotactic transplantation of neurons and therapeutic cells into the brain. The company focuses on neurosurgical instrumentation and delivery platforms designed to enable precise cell-based therapies for central nervous system indications.
When was TheraCell founded?
TheraCell was founded in 2008. It employs 1 to 10 people.
Where is TheraCell based?
TheraCell is headquartered in Northridge, United States, in the North America region.
How does TheraCell make money?
Three revenue lines are on record. Autologous Therapy Products are the primary driver. The others are allograft Products and synthetic Bone Grafts.
Who are TheraCell's main competitors?
Direct peers on record are Renishaw (Neuromate / neurosurgery), Aspen Neuroscience, BrainStorm Cell Therapeutics, Lineage Cell Therapeutics and BlueRock Therapeutics. Broad incumbents are Brainlab and Sana Biotechnology. Emerging players are Q Therapeutics, Atara Biotherapeutics and Notch Therapeutics.
Does TheraCell have an API?
No public API is recorded for TheraCell.
What industry is TheraCell in?
TheraCell's product category is Neurosurgical Cell Delivery Platforms. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery). Its SIC code is 3841.